Slide 1: Investor Presentation March 2020
March 2020 Prof. Rob Phillips ASX: UCM PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia Investor Presentation
Slide 2: Overview
OVERVIEW 03. COVID-19 and Uscom, treatment and international guidelines 02. 04. Uscom Overview Strategy, investment, Mission, Products, People SWOT 01. Uscom—global leader 05. Company Introduction in non-invasive medical Summary Uscom Q3 Results devices Results Conclusion Uscom – The Measure of Life
Slide 3: Introduction
INTRODUCTION “Uscom is an established growth stock that is now profitable, cash flow positive and with cash on hand with strong growth credentials in the current health crisis. Results for this quarter represent 15 years of product development, clinical testing, targeted corporate acquisitions and s
Slide 4: 2020: Q3 Results
2020: Q3 RESULTS* Profitable Record Cash Cash Flow Cash on Receipts Positive Hand Debt Free ~$0.35M $2.14M $0.99M $2.47M Q2 on Q3 $3.00 ↑ 449% ↑ 67% $2.47 $2.50 $2.14 $2.00 $1.48 $1.50 $M AUD Q2 $0.99 Q3 $1.00 $0.50 $0.39 $0.00 Customer Recipts Cash on Hand Cash Flow -0.28 ($0.50) * Results 1-1-20 t
Slide 5: 2020: Q3 Results
2020: Q3 RESULTS* 1. Profitable, cash flow positive, record cash receipts, cash on hand, debt free 2. Uscom China first quarter of operations – Profitable 3. Sales from China customers and COVID-19 sales 4. Europe and US COVID-19 sales beginning * Results to 23rd March 2020 Uscom – The Measure of Li
Slide 6: The Uscom Mission
THE USCOM MISSION Ambitious and growth driven Who We Are Our Vision Our Drive Uscom are the experts in circulation delivering Uscom arepractice innovative, the experts in non-invasive changing circulation To improve clinical care in A commercial A commercial ambition ambition to become to become a l
Slide 7: Multiple Products
MULTIPLE PRODUCTS Uscom SpiroSonic USCOM 1A Uscom BP+ Uscom digital ultrasonic spirometers are A non-invasive advanced hemodynamic Provides central and brachial blood high fidelity, digital, pulmonary function monitor that measures cardiovascular pressure and pulse pressure waveforms testing devices
Slide 8: Growing Global
GROWING GLOBAL • London • Beijing • Budapest • LA Operations Sydney Beijing Budapest • Singapore Offices Singapore Auckland • Sydney London • Auckland LA Multiple products, currencies and markets
Slide 9: People
PEOPLE Rob Phillips Nick Schicht Teresa Guo Lucy Lu Lebron Wei Denise Pater Rik Denicke George Ferenczi Nancy Wang Scarlett Zhang Curt Grosse Daniel Kenig Richard Scott Zsofia Kertesz Crystal Lin George Tang Susanna Sun Andrea Marosan 37 employees 4 continents 11 Nations Antonio Ferrario Szabo Gergo
Slide 10: COVID-19
COVID-19 Pandemic infectious disease Rapid global spread Not about China US Italy Australia China https://www.washingtonpost.com/graphics/2020/world/mapping-spread-new-coronavirus/ 26th March 2020
Slide 11: Treating COVID-19
TREATING COVID-19 In the absence of a vaccine, patients either recover (~90%) or arrive in ICU (~10%) ICU treatment involves respiratory and cardiovascular support as the immune system overwhelms the infection Devices: Respiratory support – ventilators Cardiovascular support – USCOM 1A Critical Care
Slide 12: COVID-19 (China)
COVID-19 (CHINA) USCOM 1A Recommended by Chinese National Health and Medical Commission of the People’s Republic of China for Treatment of Severe Coronavirus in Adults and Children The China National Health and Medical Commission of the People’s Republic of China “Protocol for Diagnosis and Treatmen
Slide 13: COVID-19 (Sepsis)
COVID-19 (SEPSIS) USCOM 1A recommended by SCCM for Pediatric Sepsis International Guidelines from US, UK, Europe, Canada, S America, India, Australia 51 Authors, 25% of authors are USCOM users or advocates Weiss SL, Alhazzani W, Flori HM et al. Surviving Sepsis Campaign International Guidelines for
Slide 14: 2020: Impact of COVID-19
2020: IMPACT OF COVID-19 1. Short term USCOM 1A emergency sales 2. Mid term USCOM 1A sales as all markets recognise need for improved ICU services 3. Longer term digital home monitoring of heart and lungs with BP+ and SpiroSonic 4. Total sales will increase as emergency response turns to structural
Slide 15: 2020: Strategy
2020: STRATEGY 1. China sales and distribution 2. New products – new revenue streams for second half 2020 3. Expand manufacturing to meet demand 4. Develop SE Asia HQ in Singapore 5. Drive global regulatory – NMPA, CE, FDA 6. Grow Europe and US sales marketing activities 7. Increase global digital m
Slide 16: UCM Investment
UCM INVESTMENT Shareholding Quality growth stock NED Tightly held CEO Invested management Ex CEO Investor 1 Undergoing revaluation Free Investor 2a Float Investor 2b 31% Investor 3 ~150M FPO UCM shares on issue Distributor ~35±10c (Current price 20c) Investor 4 China Director ~$35M Cap Value Investo
Slide 17: Health – Growth Index
HEALTH – GROWTH INDEX Australian 10yr Return per Index Australian 10yr CAGR per Index 500% 20% Health 446% Health 18.5% 400% 15% 300% 10% 200% Mean non-health 2.8% Mean non-health 38% 5% 100% 0% 0% -100% -5% 11.7 x Mean non-health return 6.6 x Mean non-health return Health vs other indices - 10yr gr
Slide 18: Corporate Analysis: SWOT
CORPORATE ANALYSIS SWOT Analysis • Strengths - Medical technology leader, profitable, cash flow positive, cash on hand and debt free, with growth history, impending new products and strong global distribution Threats - Global expansion: AU/CN/GB/HU/NZ/SG/US, defensive for applications, currencies St
Slide 19: Summary
SUMMARY 1. Profitable, cash flow positive, record cash receipts, cash on hand and debt free 2. Strong growth history at inflection point - 6 year sales growth 29% pa CAGR 3. Strong growth opportunities - Uscom China and expanding global distribution 4. Investment - Two corporate acquisitions with gl
Slide 20: 2020: Q3 Results
2020: Q3 RESULTS* Profitable Record Cash Cash Flow Cash on Receipts Positive Hand Debt Free ~$0.35M $2.14M $0.99M $2.47M Q2 on Q3 $3.00 ↑ 449% ↑ 67% $2.47 $2.50 $2.14 $2.00 $1.48 $1.50 $M AUD Q2 $0.99 Q3 $1.00 $0.50 $0.39 $0.00 Customer Recipts Cash on Hand Cash Flow -0.28 ($0.50) * Results to 23-03
Slide 21: Conclusion
CONCLUSION “Uscom has an established growth history, with rapidly transforming fundamentals and a clear strategy focused on continuing global growth Uscom is part of the Chinese Government response to the Coronavirus pandemic, and is now engaging with the emerging hot spots of the US and Europe Usco
Slide 22: March 2020
March 2020 Prof. Rob Phillips ASX: UCM PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia Investor Presentation
Slide 23: UCM – Investor Presentation April 2020
UCM – Investor Presentation April 2020 Uscom - improving the quality of life for us all